U.S. FDA Grants Priority Review for Elafibranor, a Potential New Treatment for Primary Biliary Cholangitis

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor, an oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, marking a significant step towards providing a new treatment option for patients with primary biliary cholangitis (PBC). This rare, progressive, autoimmune cholestatic liver disease primarily affects women and can lead to liver failure if untreated.

Elafibranor has shown promise in targeting multiple cell types and biological processes involved in the pathophysiology of PBC, including cholestasis, bile toxicity, inflammation, and fibrosis. The ELATIVE Phase III clinical trial demonstrated elafibranor's potential efficacy, with significant improvements in biochemical response and reductions in alkaline phosphatase (ALP) levels, an important predictor of PBC disease progression.

The simultaneous regulatory submissions to the FDA, EMA, and MHRA underscore the urgency and need for new treatment options for PBC patients. Christelle Huguet, EVP and Head of Research & Development at Ipsen, emphasized the potential of elafibranor to change the management of PBC, offering hope to patients with limited effective treatment options.

Elafibranor's safety profile was well-documented in the ELATIVE trial, with adverse events including abdominal pain, diarrhea, nausea, and vomiting occurring in more than 10% of patients. Despite these side effects, the trial's findings suggest that elafibranor could be a valuable addition to the treatment landscape for PBC, pending regulatory approval.

This development represents a collaborative effort between Ipsen and GENFIT, aiming to address the high unmet medical needs of patients with rare and life-threatening liver diseases. The progress of elafibranor through the regulatory review processes is eagerly anticipated by the medical community and patients alike.